# US 2024/0392270 A1 · Engineered lipase enzymes, manufacture and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392270 A1
- Document ID: US20240392270A1
- Status: Published application
- Kind: A1
- Application number: 18/697,203
- Filed: 2022-09-30
- Published: 2024-11-28
- Earliest claimed: 2021-09-30
- Assignees: Anagram Therapeutics, Inc.
- Applicants: Anagram Therapeutics, Inc.
- Inventors: Robert Gallotto; Alexey Margolin; Hugh Wight; Jack Greene; Mark Welch; Claes Gustafsson; Sridhar Govindarajan
- Web page: https://patentgrep.com/patent/US20240392270A1

## CPC

- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Provided are engineered lipase enzymes, methods of making such engineered lipases, dosage forms containing such engineered lipases and, methods of using such engineered lipases for treating diseases or disorders associated with reduced ability to digest and/or absorb triglycerides (fats).

## Claims

### Claim 1

A recombinant mutant microbial lipase enzyme, wherein the lipase comprises one or more of (i) increased stability at acidic pH (e.g., pH 3.0 or 4.0) relative to a corresponding wild-type microbial lipase enzyme, (ii) increased stability in the presence of a protease (e.g., a serine protease and/or an aspartic protease) relative to the corresponding wild-type microbial lipase enzyme, or (iii) at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the enzymatic activity of the corresponding wild-type microbial lipase enzyme.

### Claim 2 (depends on 1)

The lipase of claim 1, wherein the lipase comprises:
(a) a substitution of a residue at a position corresponding to position 102 of wild-type B. cepacia lipase;
(b) a substitution of a residue at a position corresponding to position 125 of wild-type B. cepacia lipase;
(c) a substitution of a residue at a position corresponding to position 137 of wild-type B. cepacia lipase;
(d) a substitution of a residue at a position corresponding to position 153 of wild-type B. cepacia lipase;
(e) a substitution of a residue at a position corresponding to position 154 of wild-type B. cepacia lipase;
(f) a substitution of a residue at a position corresponding to position 221 of wild-type B. cepacia lipase;
(g) a substitution of a residue at a position corresponding to position 227 of wild-type B. cepacia lipase;
(h) a substitution of a residue at a position corresponding to position 249 of wild-type B. cepacia lipase;
(i) a substitution of a residue at a position corresponding to position 266 of wild-type B. cepacia lipase;
(j) a substitution of a residue at a position corresponding to position 300 of wild-type B. cepacia lipase;
(k) a substitution of a residue at a position corresponding to position 39 of wild-type Burkholderia cepacia lipase;
(l) a substitution of a residue at a position corresponding to position 79 of wild-type B. cepacia lipase;
(m) a substitution of a residue at a position corresponding to position 128 of wild-type B. cepacia lipase;
(n) a substitution of a residue at a position corresponding to position 138 of wild-type B. cepacia lipase;
(o) a substitution of a residue at a position corresponding to position 161 of wild-type B. cepacia lipase;
(p) a substitution of a residue at a position corresponding to position 170 of wild-type B. cepacia lipase;
(q) a substitution of a residue at a position corresponding to position 240 of wild-type B. cepacia lipase;
(r) a substitution of a residue at a position corresponding to position 250 of wild-type B. cepacia lipase;
(s) a substitution of a residue at a position corresponding to position 260 of wild-type B. cepacia lipase;
(t) a substitution of a residue at a position corresponding to position 281 of wild-type B. cepacia lipase;
or a combination of any of the foregoing substitutions.

### Claim 3 (depends on 2)

The lipase of claim 2, wherein, in the lipase:
(a) the residue at a position corresponding to position 102 of wild-type B. cepacia lipase is substituted by Q;
(b) the residue at a position corresponding to position 125 of wild-type B. cepacia lipase is substituted by S;
(c) the residue at a position corresponding to position 137 of wild-type B. cepacia lipase is substituted by A;
(d) the residue at a position corresponding to position 153 of wild-type B. cepacia lipase is substituted by N;
(e) the residue at a position corresponding to position 154 of wild-type B. cepacia lipase is substituted by H;
(f) the residue at a position corresponding to position 221 of wild-type B. cepacia lipase is substituted by L;
(g) the residue at a position corresponding to position 227 of wild-type B. cepacia lipase is substituted by K;
(h) the residue at a position corresponding to position 249 of wild-type B. cepacia lipase is substituted by L;
(i) the residue at a position corresponding to position 266 of wild-type B. cepacia lipase is substituted by L;
(j) the residue at a position corresponding to position 300 of wild-type B. cepacia lipase is substituted by Y;
(k) the residue at a position corresponding to position 39 of wild-type B. cepacia lipase is substituted by R;
(l) the residue at a position corresponding to position 79 of wild-type B. cepacia lipase is substituted by Q;
(m) the residue at a position corresponding to position 128 of wild-type B. cepacia lipase is substituted by N;
(n) the residue at a position corresponding to position 138 of wild-type B. cepacia lipase is substituted by I;
(o) the residue at a position corresponding to position 161 of wild-type B. cepacia lipase is substituted by A;
(p) the residue at a position corresponding to position 170 of wild-type B. cepacia lipase is substituted by S;
(q) the residue at a position corresponding to position 240 of wild-type B. cepacia lipase is substituted by V;
(r) the residue at a position corresponding to position 250 of wild-type B. cepacia lipase is substituted by A;
(s) the residue at a position corresponding to position 260 of wild-type B. cepacia lipase is substituted by A;
(t) the residue at a position corresponding to position 281 of wild-type B. cepacia lipase is substituted by A;
or the lipase comprises a combination of any of the foregoing substitutions.

### Claim 4 (depends on 1, 2, 3)

The lipase of any one of claims 1-3, wherein the lipase comprises:
(a) a substitution of a D residue at a position corresponding to position 102 of wild-type B. cepacia lipase (D102);
(b) a substitution of a G residue at a position corresponding to position 125 of wild-type B. cepacia lipase (G125);
(c) a substitution of a T residue at a position corresponding to position 137 of wild-type B. cepacia lipase (T137);
(d) a substitution of an S residue at a position corresponding to position 153 of wild-type B. cepacia lipase (S153);
(e) a substitution of an N residue at a position corresponding to position 154 of wild-type B. cepacia lipase (N154);
(f) a substitution of an F residue at a position corresponding to position 221 of wild-type B. cepacia lipase (F221);
(g) a substitution of a T residue at a position corresponding to position 227 of wild-type B. cepacia lipase (T227);
(h) a substitution of an F residue at a position corresponding to position 249 of wild-type B. cepacia lipase (F249);
(i) a substitution of a V residue at a position corresponding to position 266 of wild-type B. cepacia lipase (V266);
(j) a substitution of an N residue at a position corresponding to position 300 of wild-type B. cepacia lipase (N300);
(k) a substitution of a Q residue at a position corresponding to position 39 of wild-type Burkholderia cepacia lipase (Q39);
(l) a substitution of a T residue at a position corresponding to position 79 of wild-type B. cepacia lipase (T79);
(m) a substitution of an A residue at a position corresponding to position 128 of wild-type B. cepacia lipase (A128);
(n) a substitution of a V residue at a position corresponding to position 138 of wild-type B. cepacia lipase (V138);
(o) a substitution of an L residue at a position corresponding to position 161 of wild-type B. cepacia lipase (L128);
(p) a substitution of an A residue at a position corresponding to position 170 of wild-type B. cepacia lipase (A170);
(q) a substitution of an A residue at a position corresponding to position 240 of wild-type B. cepacia lipase (A240);
(r) a substitution of a G residue at a position corresponding to position 250 of wild-type B. cepacia lipase (G250);
(s) a substitution of an S residue at a position corresponding to position 260 of wild-type B. cepacia lipase (S260);
(t) a substitution of an S residue at a position corresponding to position 281 of wild-type B. cepacia lipase (S281);
or a combination of any of the foregoing substitutions.

### Claim 5 (depends on 4)

The lipase of claim 4, wherein, in the lipase:
(a) the D residue at a position corresponding to position 102 of wild-type B. cepacia lipase is substituted by Q (D102Q);
(b) the G residue at a position corresponding to position 125 of wild-type B. cepacia lipase is substituted by S (G125S);
(c) the T residue at a position corresponding to position 137 of wild-type B. cepacia lipase is substituted by A (T137A);
(d) the S residue at a position corresponding to position 153 of wild-type B. cepacia lipase is substituted by N (S153N);
(e) the N residue at a position corresponding to position 154 of wild-type B. cepacia lipase is substituted by H (N154H);
(f) the F residue at a position corresponding to position 221 of wild-type B. cepacia lipase is substituted by L (F221L);
(g) the T residue at a position corresponding to position 227 of wild-type B. cepacia lipase is substituted by K (T227K);
(h) the F residue at a position corresponding to position 249 of wild-type B. cepacia lipase is substituted by L (F249L);
(i) the V residue at a position corresponding to position 266 of wild-type B. cepacia lipase is substituted by L (V266L);
(j) the N residue at a position corresponding to position 300 of wild-type B. cepacia lipase is substituted by Y (N300Y);
(k) the Q residue at a position corresponding to position 39 of wild-type B. cepacia lipase is substituted by R (Q39R);
(l) the T residue at a position corresponding to position 79 of wild-type B. cepacia lipase is substituted by Q (T79Q);
(m) the A residue at a position corresponding to position 128 of wild-type B. cepacia lipase is substituted by N (A128N);
(n) the V residue at a position corresponding to position 138 of wild-type B. cepacia lipase is substituted by I (V1381);
(o) the L residue at a position corresponding to position 161 of wild-type B. cepacia lipase is substituted by A (L161A);
(p) the A residue at a position corresponding to position 170 of wild-type B. cepacia lipase is substituted by S (A170S);
(q) the A residue at a position corresponding to position 240 of wild-type B. cepacia lipase is substituted by V (A240V);
(r) the G residue at a position corresponding to position 250 of wild-type B. cepacia lipase is substituted by A (G250A);
(s) the S residue at a position corresponding to position 260 of wild-type B. cepacia lipase is substituted by A (S260A);
(t) the S residue at a position corresponding to position 281 of wild-type B. cepacia lipase is substituted by A (S281A);
or the lipase comprises a combination of any of the foregoing substitutions.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The lipase of any one of claims 1-5, wherein the lipase comprises one, two, three, four, five, six, seven, eight, nine, ten, or more than ten mutations relative to the corresponding wild-type microbial lipase.

### Claim 7 (depends on 5, 6)

The lipase of claim 5 or 6, wherein the lipase comprises:
(a) the D102Q, N154H, and F221L substitutions;
(b) the D102Q, G125S, N154H, F221L, V266L, and N300Y substitutions;
(c) the T79Q, D102Q, G125S, T137A, N154H, F221L, T227K, F249L, V266L, and N300Y substitutions;
(d) the T79Q, D102Q, G125S, T137A, N154H, F221L, T227K, V266L, S281A, and N300Y substitutions;
(e) the T79Q, D102Q, G125S, S153N, N154H, F221L, T227K, V266L, S281A, and N300Y substitutions;
(f) the T79Q, D102Q, G125S, S153N, N154H, F221L, F249L, G250A, V266L, and N300Y substitutions;
(g) the T79Q, D102Q, G125S, S153N, N154H, F221L, F249L, V266L, S281A, and N300Y substitutions;
(h) the T79Q, D102Q, G125S, N154H, F221L, T227K, F249L, V266L, S281A, and N300Y substitutions;
(i) the D102Q, G125S, T137A, S153N, N154H, F221L, T227K, F249L, V266L, and N300Y substitutions;
(j) the D102Q, G125S, T137A, S153N, N154H, F221L, T227K, G250A, V266L, and N300Y substitutions;
(k) the D102Q, G125S, T137A, N154H, F221L, T227K, G250A, V266L, S281A, and N300Y substitutions;
(l) the D102Q, G125S, S153N, N154H, F221L, T227K, F249L, G250A, V266L, and N300Y substitutions; or
(m) the D102Q, G125S, S153N, N154H, F221L, T227K, F249L, V266L, S281A, and N300Y substitutions.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The lipase of any one of claims 1-7 wherein the lipase is a α/β-hydrolase lipase.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The lipase of any one of claims 1-8, wherein the lipase comprises a serine-histidine-aspartate active triad.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The lipase of any one of claims 1-9, wherein the lipase comprises a hydrophobic lid that opens to allow for the binding and/or hydrolysis of a lipid.

### Claim 11 (depends on 10)

The lipase of claim 10, wherein the hydrophobic lid opens sufficiently to allow for the binding and/or hydrolysis of a triglyceride having a chain length of greater than eight carbons.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The lipase of any one of claims 1-11, wherein the lipase comprises a calcium binding site, wherein, when calcium is bound to the calcium binding site, the lipase is stabilized.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The lipase of any one of claims 1-12, wherein the lipase comprises an oxyanion hole, wherein the oxyanion hole stabilizes a negatively charged intermediate generated during fatty acid bond hydrolysis.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The lipase of any one of claims 1-13, wherein the lipase is a Family 1 bacterial lipase.

### Claim 15 (depends on 14)

The lipase of claim 14, wherein the lipase is a I.1, I.2, or I.3 subfamily bacterial lipase.

### Claim 16 (depends on 15)

The lipase of claim 15, wherein the lipase is a I.1 or I.2 subfamily bacterial lipase.

### Claim 17 (depends on 16)

The lipase of claim 16, wherein the lipase is a I.2 subfamily bacterial lipase.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The lipase of any one of claims 1-17, wherein the lipase is a Burkholderia, Pseudomonas, or Chromobacterium lipase.

### Claim 19 (depends on 18)

The lipase of claim 18, wherein the lipase is a Burkholderia cepacia, Burkholderia glumae, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonas luteola, or Chromobacterium viscosum lipase.

### Claim 20 (depends on 19)

The lipase of claim 19, wherein the lipase is a Burkholderia cepacia lipase.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The lipase of any one of claims 1-20, wherein the lipase comprises a S residue at a position corresponding to position 87 of wild-type B. cepacia (S87), a D residue at a position corresponding to position 264 of wild-type B. cepacia (D264), and a H residue at a position corresponding to position 286 of wild-type B. cepacia (H286).

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The lipase of any one of claims 1-21, wherein the lipase comprises the amino acid sequence of any one of SEQ ID NOs: 2-14, or an amino acid sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 2-14.

### Claim 23

A recombinant mutant microbial lipase enzyme comprising a substitution, or combination of substitutions, listed in TABLE 1 or TABLE 2.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The lipase of any one of claims 1-23, wherein the lipase has a half-life of at least 75 minutes, 100 minutes, 125 minutes, 150 minutes, 175 minutes, 180 minutes, 185 minutes, 190 minutes, 195 minutes, or 200 minutes in the presence of a serine protease.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The lipase of any one of claims 1-24, wherein the lipase has at least 0.5 fold, 1 fold, 1.5 fold, 2 fold, 2.5 fold, or 3 fold higher stability in the presence of a serine protease, compared to the corresponding wild-type lipase.

### Claim 26 (depends on 24, 25)

The lipase of claim 24 or 25, wherein the serine protease is Aspergillus melleus protease.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The lipase of any one of claims 1-26, wherein the lipase has a half-life of at least 50 minutes, 75 minutes, 100 minutes, 125 minutes, 130 minutes, 135 minutes, 140 minutes, 145 minutes, or 150 minutes at about pH 3.0.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The lipase of any one of claims 1-27, wherein the lipase has at least 1.5 fold, 2 fold, 2.5 fold, or 3 fold higher stability at about pH 3.0, compared to the corresponding wild-type lipase.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The lipase of any one of claims 1-28 wherein the lipase has a half-life of at least 50 minutes, 75 minutes, 100 minutes, 125 minutes, 150 minutes, 175 minutes, 200 minutes, 225 minutes, 230 minutes, or 235 minutes in the presence of an aspartic protease (e.g., at pH 3.6).

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The lipase of any one of claims 1-29, wherein the lipase has at least 1.5 fold, 2 fold, 2.5 fold, 3 fold, 3.5 fold, or 4 fold higher stability in the presence of an aspartic protease (e.g., at pH 3.6), compared to the corresponding wild-type lipase.

### Claim 31 (depends on 29, 30)

The lipase of claim 29 or 30, wherein the aspartic protease is pepsin.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The lipase of any one of claims 1-31 wherein the lipase has a half-life of at least 50 minutes, 75 minutes, 100 minutes, 125 minutes, 150 minutes, 175 minutes, 180 minutes, 185 minutes, 190 minutes, 195 minutes, or 200 minutes in the presence of pancreatin.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The lipase of any one of claims 1-32, wherein the lipase has at least 0.5 fold, 1 fold, 1.5 fold, 2 fold, 2.5 fold, or 3 fold higher stability in the presence of pancreatin, compared to the corresponding wild-type lipase.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The lipase of any one of claims 1-33, wherein the lipase has at least 0.5 fold, 1 fold, 1.5 fold, 2 fold, 2.5 fold, or 3 fold higher activity at about pH 3.0, compared to the corresponding wild-type lipase.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The lipase of any one of claims 1-34, wherein the lipase has a specific activity at pH 3.0 of at least 300, 400, 500, 600, 700, 800, 900, or 1,000 μmol fatty acids (FA) produced/min/mg of lipase towards a long-chain triglyceride substrate including 37% DHA triglyceride and 22% oleic acid triglyceride or triolein.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The lipase of any one of claims 1-35, wherein the lipase has a specific activity at pH 4.0, pH 5.0, or pH 6.0 of at least 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, or 2,000 μmol fatty acids (FA) produced/min/mg of lipase towards a long-chain triglyceride substrate including 37% DHA triglyceride and 22% oleic acid triglyceride or triolein.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The lipase of any one of claims 1-36, wherein the lipase has a specific activity at pH 7.0 of at least 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, or 2,000 μmol fatty acids (FA) produced/min/mg of lipase towards a long-chain triglyceride substrate including 37% DHA triglyceride and 22% oleic acid triglyceride or triolein.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The lipase of any one of claims 1-37, wherein the lipase preferentially hydrolyzes the sn-1 and sn-3 positions on a triglyceride.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The lipase of any one of claims 1-38, wherein the lipase enzymatic activity (e.g., specific activity) is not inhibited by bile salts.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The lipase of any one of claims 1-39, wherein the lipase does not require a colipase.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The lipase of any one of claims 1-40, wherein the lipase is not cross-linked and/or crystallized.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The lipase of any one of claims 1-41, wherein the lipase remains sufficiently active at a pH in the range of 3.5 to 7.0 to hydrolyze long-chain poly-unsaturated fatty acids (LCPUFAs), e.g., DHA and EPA, or long-chain triglycerides, e.g., oleic acid or triolein, in the gastrointestinal tract of a subject.

### Claim 43 (depends on 42)

The lipase of claim 42, wherein the lipase is at least 2 fold, 10 fold, 100 fold or 1,000 fold more active than pancrelipase when tested under the same conditions.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The lipase of any one of claims 1-43, wherein more than 50%, 60%, 70%, 80%, or 90% of the lipase remains active in the fed-state stomach of a subject for 60-120 minutes.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The lipase of any one of claims 1-44, wherein the lipase digests greater than 20%, 30%, 40%, or 50% of ingested fats in the stomach of a subject to fatty acids and monoglycerides.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The lipase of any one of claims 1-45, wherein more than 50%, 60%, 70%, 80%, or 90% of the lipase remains active through the small intestine of a subject from about 240 to about 360 minutes.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The lipase of any one of claims 1-46, wherein the lipase digests greater than 50%, 60%, 70%, 80%, or 90% of ingested fats in the small intestine of a subject to fatty acids and monoglycerides.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The lipase of any one of claims 1-47, wherein the lipase increases absorption of long-chain unsaturated fatty acids to the plasma in a subject within 30 minutes, 45 minutes, 60 minutes, 90 minutes, or 120 minutes by more than 25%, 35%, 50%, 100%, or 200% relative to the same subject when that subject has not been administered the lipase, or relative to a similar subject that has not been administered the lipase.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The lipase of any one of claims 1-48, wherein the lipase increases absorption of fat-soluble vitamins (e.g., vitamin A, vitamin D, vitamin E, vitamin K).

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The lipase of any one of claims 1-49, wherein the lipase increases absorption of choline.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A nucleic acid encoding the lipase of any one of claims 1-50.

### Claim 52 (depends on 51)

An expression vector comprising a nucleic acid sequence of claim 51.

### Claim 53 (depends on 52)

The expression vector of claim 52, wherein the nucleic acid sequence encoding the recombinant mutant lipase is codon optimized for expression in a heterologous cell.

### Claim 54 (depends on 53)

The expression vector of claim 53, wherein the heterologous cell is a Burkholderia cepacia, Burkholderia glumae, Pseudomonas fluorescens, Chromobacterium viscosum, Pseudomonas luteola, Pseudomonas fragi, or Escherichia coli cell.

### Claim 55 (depends on 52, 53, 54)

A cell comprising the expression vector of any one of claims 52-54.

### Claim 56 (depends on 55)

The cell of claim 55, wherein the cell is a Burkholderia cepacia, Burkholderia glumae, Pseudomonas fluorescens, Chromobacterium viscosum, Pseudomonas luteola, or Escherichia coli cell.

### Claim 57 (depends on 55, 56)

A method of producing a recombinant mutant microbial lipase enzyme, the method comprising growing the cell of claim 55 or 56 under conditions so that the host cell expresses the recombinant mutant microbial lipase enzyme, and purifying the recombinant mutant microbial lipase enzyme.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A pharmaceutical composition comprising the lipase of any one of claims 1-50, and a pharmaceutically acceptable carrier and/or an excipient.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58, further comprising a microbial protease, and/or a microbial amylase.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the protease is an Aspergillus melleus protease and/or the amylase is an Aspergillus oryzae amylase.

### Claim 61 (depends on 58, 59, 60)

The pharmaceutical composition of any one of claims 58-60, wherein the composition is formulated as an oral dosage form.

### Claim 62 (depends on 58, 59, 60, 61)

The pharmaceutical composition of any one of claims 58-61, wherein the composition is a formulated as a powder, granulate, pellet, micropellet, liquid, or a tablet.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The pharmaceutical composition of any one of claims 58-62, wherein the composition is encapsulated in a capsule or formulated as a tablet dosage form.

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The pharmaceutical composition of any one of claims 58-63, wherein the composition does not comprise an enteric coating.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58, 59, 60, 61, 62, 63, 64)

A method of treating a disease or disorder associated with a reduced ability to digest or absorb lipids, resulting in an elevated amount of undigested lipid, in a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 58-64, thereby treating the disease or disorder in the subject.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58, 59, 60, 61, 62, 63, 64)

A method of treating maldigestion or malabsorption of lipids in a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 58-64, thereby treating the disease or disorder in the subject.

### Claim 67 (depends on 66)

The method of claim 66, wherein the subject exhibits low level secretion of pancreatic enzymes or has a physiological condition that affects fat hydrolysis or fat absorption (e.g., reduced gastric, duodenal, liver, bile, or gallbladder function); reduced gastrointestinal transit, motility, mixing, emptying; or reduced intestinal mucosa function (e.g., induced by mucosal damage) that results in fat maldigestion or fat malabsorption or a fatty acid deficiency.

### Claim 68 (depends on 66, 67)

The method of claim 66 or 67, wherein the maldigestion or malabsorption of lipids is associated with a disease or disorder selected from exocrine pancreatic insufficiency (EPI), malabsorption syndrome, cystic fibrosis, chronic pancreatitis, acute pancreatitis, Schwachman-Diamond syndrome, a fatty acid disorder, Familial lipoprotein lipase deficiency, Johanson-Blizzard syndrome, Zollinger-Ellison syndrome, Pearson marrow syndrome, short-bowel syndrome, liver disease, primary biliary atresia, cholestasis, celiac disease, fatty liver disease, pancreatitis, diabetes, aging, cancer of the pancreas, stomach, small intestine, colon, rectal/anal, liver, hepatic, gallbladder, or, esophagus, cachexia, or a gastrointestinal disorder (e.g., Crohn's disease, irritable bowel syndrome, or ulcerative colitis), surgical invention of the stomach, small intestine, liver, gallbladder or pancreas.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58, 59, 60, 61, 62, 63, 64)

A method of improving the absorption of fatty acids in a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 58-64, thereby improving absorption of fatty acids in the subject.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58, 59, 60, 61, 62, 63, 64)

A method of increasing the amount of fatty acids in plasma, erythrocytes, or a tissue of a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 58-64, thereby increasing the amount of fatty acids in the subject.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58, 59, 60, 61, 62, 63, 64)

A method of increasing the ratio of omega-3 to omega-6 fatty acids in plasma, erythrocytes, or a tissue of a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 58-64, thereby increasing the amount of fatty acids in the subject.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method of reducing the amount of fatty acids in the stool of a subject in need thereof, the method comprising administering to the subject an effective amount of the lipase of any one of claims 1-50, or the pharmaceutical composition of any one of claims 50-56, thereby reducing the amount of fatty acids in the stool of the subject.

### Claim 73 (depends on 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 65-72, wherein the fatty acids are long-chain poly-unsaturated fatty acids (LCPUFAs).

### Claim 74 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 65-73, wherein the fatty acids are omega-3 fatty acids.

### Claim 75 (depends on 74)

The method of claim 74, wherein the omega-3 fatty acids are DHA, EPA, or DPA.

### Claim 76 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 65-75, wherein the subject is administered less than 400, 600, 800, or 1,000 mg of the lipase or pharmaceutical composition per day.

### Claim 77 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 65-76, wherein the lipase or pharmaceutical composition is administered in combination with a fat soluble vitamin (e.g., vitamin A, D, E, or K), an acid blocker, or a nutritional formula containing triglycerides.

### Claim 78 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 65-77, wherein the subject is a mammal.

### Claim 79 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 65-78, wherein the subject is a human.
